Biogen bets big on Sangamo's zinc fingers to treat Alzheimer's
Friday, February 28, 2020 - 16:50
in Health & Medicine
Biogen will pay the biotech firm $350 million upfront and get rights to its therapies for up to 12 neurological diseases